Juliette Mazereeuw-Hautier
Prof Juliette Mazereeuw-Hautier is an expert in Dermatology at Centre Hospitalier Universitaire de Toulouse (France). As of October 2026, ScienceLeadR ranks Juliette Mazereeuw-Hautier in the top 1% of experts worldwide for Ichthyosis, Keratosis and Skin Abnormalities. Juliette Mazereeuw-Hautier has authored 422 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 11 of them ongoing. SLR score: 1,488 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Genetics - Infectiology - Pediatrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 422
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Future research priorities in epidermal differentiation disorders. PMID 42841824 — research, dermatology | J Invest Dermatol | 2026 | 0 |
| Acute Pustular Facial Eruption in a 5-Year-Old Boy. PMID 42634963 — amoxicillin, skin diseases, drug eruptions, dermatology, child | Pediatr Dermatol | 2026 | 0 |
| Consensus Recommendations for Management of Darier Disease: A Practical Approach. PMID 42455252 — genes, retinoids, quality of life, genetic testing, darier disease, diagnosis, therapeutics, wounds and injuries | Dermatol Ther (Heidelb) | 2026 | 0 |
| Darier disease-A review highlighting new insights from the Darier Disease International Task Force. PMID 42223188 — genes, sexually transmitted diseases, skin diseases, darier disease, acantholysis, therapeutics | J Eur Acad Dermatol Venereol | 2026 | 0 |
| The Candle Spot: An Unreported Sign of SULT2B1-nEDD. PMID 42223411 — sexually transmitted diseases, dermatology | Acta Derm Venereol | 2026 | 0 |
Clinical Studies 24
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasis 2023-503859-10-00 — ustekinumab, safety, adolescent, psoriasis, child | Phase 3 | Active not recruiting | 2024 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to 12 Years of Age With Severe Alopecia Areata 2024-515438-33-00 — safety, alopecia areata, child, alopecia | Phase 3 | Active not recruiting | 2026 |
| Phase 2 study evaluating the efficacy of injectable gentamicin in hereditary ichthyosis GENTIC 2023-505570-15-00 — ichthyosis | Phase 2 | Recruiting | 2025 |
| EBUL0 A 20 Week Multicentre Open Study Assessing the Efficacy and Safety of Apremilast in Patients 6 years of age with Epidermolysis bullosa simplex generalized 2023-508794-83-00 — safety, epidermolysis bullosa simplex, epidermolysis bullosa | Phase 2 | Recruiting | 2025 |
| Dupilumab step down strategy to maintain remission in adult and adolescents patients with atopic dermatitis a non inferiority randomized trial 2022-501179-23-00 — dermatitis, adolescent, dermatitis, atopic | Phase 4 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map